Table 3.

The results of the univariate and multivariate Cox regression analysis.

Variable	PFS				OS
	Log Rank		Cox Regression		Log Rank		Cox Regression
	x2	p	HR (95%CI)	p	x2	p	HR (95%CI)	p
Age (years)	5.879	0.015*	3.532(1.301-9.593)	0.013	9.696	0.002*	5.644(1.430-22.277)	0.013
Menopausal Status	4.524	0.033*			4.644	0.031*
Tumor Location	0.233	0.629			0.078	0.780
Histologic Type	2.992	0.084			2.16	0.142
Clinical Stage	16.067	<0.001*			19.806	<0.001*
Clinical T Stage	1.273	0.736			6.472	0.091
Clinical N Stage	9.238	0.010*			16.255	<0.001*
Clinical M Stage	15.472	<0.001*	2.977(1.217-7.283)	0.017	19.46	<0.001*	3.499(0.962-12.727)	0.057
ER Status	3.902	0.048*			3.678	0.055
PR Status	5.084	0.024*			5.357	0.021*
HER2 Status	0.027	0.870			0.035	0.853
Molecular Subtype	4.626	0.201			4.763	0.190
Ki-67	4.174	0.041*			1.157	0.282
Treatment	5.994	0.050			4.931	0.085
SUVmax	7.058	0.008*			2.028	0.154
SUVmin	5.359	0.021*	4.240(1.814-9.910)	0.001	2.598	0.107
SUVmean	3.950	0.047*			1.686	0.194
SUVpeak	6.130	0.013*			1.685	0.194
MTV	1.772	0.183			3.848	0.050
TLG	2.891	0.089			3.758	0.053
Rad-score	4.261	0.039*	2.660(1.029-6.880)	0.044	6.930	0.008*	3.627(1.171-11.241)	0.026

The clinicopathological factors and Rad-score were analyzed by the log-rank method in univariate analysis, and then characteristics with p < 0.05 were taken into the multivariate Cox regression to construct the final model. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; Rad-score, radiomic score. *P < 0.05.